AACE2019:2型糖尿病可使老年女性短期骨折风险加倍

2019-05-07 国际糖尿病编辑部 国际糖尿病

2型糖尿病(T2DM)是引起骨骼损伤以及骨脆性增加的独立危险因素。在刚刚结束的第28届美国临床内分泌医师协会年会(AACE2019)上,一项基于弗雷明汉姆研究初始受试者及其后代队列(Framingham Original and Offspring Cohorts)进行的分析显示,在1年内,T2DM女性患者的骨折风险是无糖尿病女性的两倍!

2型糖尿病(T2DM)是引起骨骼损伤以及骨脆性增加的独立危险因素。在刚刚结束的第28届美国临床内分泌医师协会年会(AACE2019)上,一项基于弗雷明汉姆研究初始受试者及其后代队列(Framingham Original and Offspring Cohorts)进行的分析显示,在1年内,T2DM女性患者的骨折风险是无糖尿病女性的两倍!

美国哈佛大学医学院Samelson教授领导的研究团队充分评估了弗雷明汉姆研究初始受试者及其后代队列研究的数据特征,该研究在上世纪90年代对2105例女性和1130例男性(平均年龄为67岁)进行了骨质疏松症的基线调查。其中有7%女性和13%男性患有2型糖尿病(平均病程为8年);其中,63%的女性和51%的男性均服用降糖药物治疗。

在之后的9年随访期内发现,2型糖尿病患者中分别有37%的女性和11%的男性发生骨折,而非糖尿病患者中有30%的女性和16%的男性发生骨折。随访第1年时发现,2型糖尿病患者发生骨折的风险高出非2型糖尿病患者一倍以上(HR=2.23)。相比于非糖尿病患者,糖尿病患者病程每增加5年,2年内骨折发生风险随之增加(HR=1.28)。另外,使用降糖药物的患者骨折发生风险也增加(HR=1.7)。然而,2型糖尿病对长期骨折发生风险无统计学意义上的显著影响。

此研究结果表明老年2型糖尿病女性患者短期骨折发生风险增加,该结果可为骨折风险分层以及适当的临床干预提供一定的依据。

研究者述评:“在通常情况下,我们需要长时间随访观察骨折的发生率并进行相关研究,基于弗雷明汉姆研究初始受试者及其后代队列研究的规模和特征,我们能够观察1年和2年以及10年以上的骨折风险。结果显示糖尿病患者的短期(1~2年)骨折风险显著增加,而长期(10年以上)骨折风险增加并不显著。我们下一步将研究特定的药物使用、研究疾病严重程度的不同标志物,以及糖尿病患者骨折的其他危险因素。”

原始出处:
Dufour A, et al. Diabetes increases short-term but not long-term risk of fracture: A community-based study. Presented at: AACE Annual Scientific and Clinical Congress; April 24-28,2019; Los Angeles.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655946, encodeId=1b561655946f2, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 22 02:14:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699207, encodeId=6f95169920edd, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Nov 14 04:14:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382990, encodeId=85f11382990fc, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 09 13:14:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390409, encodeId=219c139040973, content=<a href='/topic/show?id=22c6101695c9' target=_blank style='color:#2F92EE;'>#骨折风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101695, encryptionId=22c6101695c9, topicName=骨折风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu May 09 13:14:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042433, encodeId=05651042433ac, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed May 08 01:14:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2019-06-22 智智灵药
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655946, encodeId=1b561655946f2, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 22 02:14:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699207, encodeId=6f95169920edd, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Nov 14 04:14:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382990, encodeId=85f11382990fc, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 09 13:14:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390409, encodeId=219c139040973, content=<a href='/topic/show?id=22c6101695c9' target=_blank style='color:#2F92EE;'>#骨折风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101695, encryptionId=22c6101695c9, topicName=骨折风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu May 09 13:14:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042433, encodeId=05651042433ac, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed May 08 01:14:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2019-11-14 zgwhgch
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655946, encodeId=1b561655946f2, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 22 02:14:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699207, encodeId=6f95169920edd, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Nov 14 04:14:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382990, encodeId=85f11382990fc, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 09 13:14:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390409, encodeId=219c139040973, content=<a href='/topic/show?id=22c6101695c9' target=_blank style='color:#2F92EE;'>#骨折风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101695, encryptionId=22c6101695c9, topicName=骨折风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu May 09 13:14:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042433, encodeId=05651042433ac, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed May 08 01:14:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655946, encodeId=1b561655946f2, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 22 02:14:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699207, encodeId=6f95169920edd, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Nov 14 04:14:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382990, encodeId=85f11382990fc, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 09 13:14:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390409, encodeId=219c139040973, content=<a href='/topic/show?id=22c6101695c9' target=_blank style='color:#2F92EE;'>#骨折风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101695, encryptionId=22c6101695c9, topicName=骨折风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu May 09 13:14:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042433, encodeId=05651042433ac, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed May 08 01:14:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1655946, encodeId=1b561655946f2, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 22 02:14:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699207, encodeId=6f95169920edd, content=<a href='/topic/show?id=1349166054' target=_blank style='color:#2F92EE;'>#AACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1660, encryptionId=1349166054, topicName=AACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ca229920897, createdName=zgwhgch, createdTime=Thu Nov 14 04:14:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382990, encodeId=85f11382990fc, content=<a href='/topic/show?id=b4c118301c' target=_blank style='color:#2F92EE;'>#ACE2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1830, encryptionId=b4c118301c, topicName=ACE2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 09 13:14:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1390409, encodeId=219c139040973, content=<a href='/topic/show?id=22c6101695c9' target=_blank style='color:#2F92EE;'>#骨折风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101695, encryptionId=22c6101695c9, topicName=骨折风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Thu May 09 13:14:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042433, encodeId=05651042433ac, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed May 08 01:14:00 CST 2019, time=2019-05-08, status=1, ipAttribution=)]
    2019-05-08 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Int J Cardiol:房颤和2型糖尿病患者抗血栓治疗的差距

由此可见,尽管有明确的指南建议进行抗凝治疗,但几乎一半的高危AF糖尿病和ASCVD患者未接受抗凝治疗,突出了在临床实践中管理这些患者临床改进的挑战和潜力。

FDA批准Qternmet XR治疗2型糖尿病

阿斯利康近日宣布,FDA已经批准Qternmet XR(达格列嗪/沙格列汀/二甲双胍)作为2型糖尿病的口服辅助治疗方法。Qternmet XR实现了SGLT-2抑制剂Farxiga(达格列嗪)、DPP-4抑制剂Onglyza(沙格列汀)和盐酸二甲双胍的三联给药方案。

Diabetes Obes Metab:2型糖尿病与心血管事件和全因死亡率之间关系

由此可见,传统的血管危险因素无法解释由于T2DM导致的大量心血管风险和全因死亡率增加。未来的研究应侧重于确定非经典途径,这可能进一步解释由于T2DM导致的心血管和死亡风险增加。

Diabetes Obes Metab:心外膜和心包脂肪组织与2型糖尿病患者的舒张和收缩功能降低有关

由此可见,与对照者相比,T2D患者与心肌密切相关的脂肪组织更多,并与T2D的功能性心肌指标相关。

Circulation:2型糖尿病的诊断年龄与心血管和死亡风险的关联

由此可见,诊断T2DM的年龄对于生存和心血管风险具有重要的预后价值,对于确定临床决策和指导性治疗的危险因素干预的时间和强度具有重要意义。这些观察结局扩大了对年轻个体预防/延迟T2DM发作的支持力度。

Circulation:2型糖尿病的心血管风险和危险因素管理

由此可见,与T2DM男性患者相比,T2DM女性患者心血管风险的相对增加率并没有显著提高,但处方中持续存在的性别差异应该促使人们更加努力地提高女性和男性糖尿病护理的标准和公平性。